UNSPSC 51183404: Repaglinide

This classification denotes an anti-diabetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 668Z8C33LU. European Medicines Agency schedules Repaglinide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10280MIG. Repaglinide generally arises in the molecular formula C27H36N2O4.

UNSPSC 51183404 Repaglinide, a Commodity code, covers generic pharmaceutical products supplied through state and local cooperative purchasing arrangements to government healthcare facilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) — administered by the Minnesota Department of Administration's Office of State Procurement — recently issued an RFP for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities in Minnesota, Oregon, and other member jurisdictions. State and local governments procuring under this code are acquiring branded and generic medications for healthcare operations, including hospitals, clinics, and other medical facilities within cooperative purchasing networks. Issuing bodies include state procurement offices acting as contract administrators on behalf of multiple member states and localities, with MMCAP serving as the contracting vehicle for multi-state purchasing. Vendors must meet cGMP and Drug Supply Chain Security Act (DSCSA) compliance, maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), and maintain comprehensive insurance including $5,000,000 in commercial general liability and $2,000,000 in network security and privacy liability.

The code shows recent activity concentrated in the Upper Midwest and Pacific Northwest through MMCAP's multi-state cooperative purchasing model. MMCAP's RFP (Solicitation S1070000015802), posted January 20, 2026, and due March 26, 2026, seeks manufacturers to supply pharmaceuticals with detailed product information including NDC codes, SKUs, UPCs, strength, dosage form, packaging configurations, and manufacturing locations. Pricing is weighted heavily at 75 percent of evaluation, with compliance, EDI capability, administrative fees, and pricing structures accounting for the remainder. All products must be available in the marketplace by May 15, 2026, with awarded vendors' contracts effective July 1, 2026, for an initial two-year term with optional extensions. The contract carries a 3 percent administrative fee and performance penalties ranging from $200 to $1,500 per violation. Specific award values are not disclosed in the solicitation materials.